Orient Europharma Co (ROCO:4120) Other Financing: NT$466 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4120 Orient Europharma Co Ltd ROCO:4120
60 GF Score
Price NT$44.40
GF Value NT$44.98
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Orient Europharma Co Other Financing?

Orient Europharma Co ROCO:4120 +0.91% 60 Other Financing is NT$466 Mil as of Dec. 2025. GuruFocus rates ROCO:4120 with a GF Score™ of 60/100 and a GF Value™ of NT$44.98 (Fairly Valued). The stock has 4 warning signs investors should review.

Orient Europharma Co's Other Financing for the three months ended in Dec. 2025 was NT$-6 Mil.

Orient Europharma Co's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was NT$466 Mil.

Orient Europharma Co Other Financing Historical Data

* Premium members only.

The historical data trend for Orient Europharma Co's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orient Europharma Co Other Financing Chart

Orient Europharma Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -300.04 -4.34 0.14 -65.52 566.94

Orient Europharma Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -41.25 -0.54 -9.24 481.65 -5.98
ROCO:4120
60GF Score
Orient Europharma Co Ltd ROCO:4120
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orient Europharma Co Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$466 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of NT$466 Mil mean?
Orient Europharma Co (ROCO:4120) has a Other Financing of NT$466 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Orient Europharma Co and its competitors.
Is Orient Europharma Co's Other Financing too high?
Orient Europharma Co's current Other Financing is NT$466 Mil. Overall, Orient Europharma Co has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Orient Europharma Co's Other Financing compare to ZTS and UTHR?
Orient Europharma Co's Other Financing of NT$466 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Drug Manufacturers company?
A good Other Financing depends on the Drug Manufacturers industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Orient Europharma Co and its competitors. Orient Europharma Co's current Other Financing is NT$466 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Europharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Europharma Co (ROCO:4120) is currently considered Fairly Valued. The stock's GF Value™ is NT$44.98, compared to a current price of NT$44.40 — trading 1.3% below its estimated fair value. The current Other Financing is NT$466 Mil. Orient Europharma Co's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Orient Europharma Co (ROCO:4120), the current Other Financing is NT$466 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orient Europharma Co (ROCO:4120) Overvalued in 2026?

Based on GuruFocus' analysis, Orient Europharma Co stock appears to be undervalued. The current stock price of NT$44.40 is trading 1.3% below its estimated GF Value™ of NT$44.98. GuruFocus considers Orient Europharma Co to be Fairly Valued.

Key valuation signals for ROCO:4120:

  • Other Financing: NT$466 Mil
  • GF Value™: NT$44.98 vs. price of NT$44.40 (1.3% below fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the ROCO:4120 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orient Europharma Co Business Description

Address 13th Floor, No. 128, Chengde Road, Section 6, Beitou District, Taipei, TWN, 112052
Orient Europharma Co Ltd is a Taiwan-based company engaged in the wholesale of Western Pharmaceutical and Medical Devices. The firm also manufactures drugs and medicines, Beverages, Cleaning Preparations, Cosmetics, Medical Devices, and Other Food Products. Its products cover various therapeutic areas, including the central nervous system, cardiovascular, diabetes, allergy, cosmetics, and health supplements. The company's segments include: Western Pharma BU which includes manufacture and sale of pharmaceutical and cosmetic products; and Nutricare BU includes sale of various nutrition supplements and consumable healthcare products. It derives maximum revenue from Western Pharma BU segment. Geographically, it operates in Taiwan, China, and Southeast Asia.
60GF Score

Get the complete analysis for ROCO:4120

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$44.40
Price
NT$44.98
GF Value